Thujones are a pooled constituent bucket for the alpha- and beta-thujone monoterpene ketones that appear in thujone-bearing oils such as wormwood, mugwort, sage, and low-level blue-yarrow profiles. The strongest live evidence base is toxicological and regulatory rather than benefit-facing: current accessible sources consistently emphasize GABAA-linked neuroactivity, seizure risk at excessive exposure, and the need to distinguish mixed-thujone data from single-isomer records. For AromaForge, grouped thujones should be handled primarily as an identity-and-safety topic, with honest acknowledgment that the literature often evaluates alpha-thujone alone or alpha,beta mixtures instead of a neatly standardized commercial pooled constituent.
Chemical identity and composition
PubChem's generic 3-thujanone record provides the shared C10H16O skeleton and synonym coverage that includes 'Thujone (a- and b- mixture)', while separate PubChem entries also exist for alpha-thujone and beta-thujone. The local archive already uses the grouped thujones label in blue yarrow at 0.43%, while wormwood-common is tracked with separate beta-thujone values up to 64.6%. Because public databases mix skeleton, isomer, and racemate records, this grouped file should stay explicit that it summarizes the alpha/beta thujone family rather than a single stereochemically uniform molecule.
Aroma and practical use
- Use the recorded herbal, camphoraceous, sage-like, sharp, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 toxicological assessment review concluded that thujone is neurotoxic, described animal evidence for GABAA-linked excitation and convulsions, and estimated that allowable daily intakes from herbal preparations and diet were on the order of 3-7 mg per day despite important remaining knowledge gaps.
This is one of the clearest synthesis papers for grouped thujone risk framing, but it is a review rather than new primary experimentation.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A 2010 risk-assessment paper used benchmark-dose modeling and proposed an acceptable daily intake of 0.11 mg/kg body weight per day for thujone based on seizure-related rat data and newer chronic-toxicity interpretation.
The paper is directly useful for exposure framing, though it remains a risk-assessment exercise built on animal data.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
The National Toxicology Program's two-year gavage study reported dose-related seizures in rats and mice exposed to alpha,beta-thujone, early deaths at the highest rat dose, and some evidence of carcinogenic activity in male rats but not in mice or female rats.
This is the strongest accessible long-term toxicology source reviewed for grouped thujones.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 chick study reported that centrally administered alpha- and beta-thujone both produced anxiogenic-like effects at 78 nmol, while only alpha-thujone reversed stress-induced GABAA receptor recruitment in that model.
The paper is useful because it compares both isomers directly, but it is still a specialized animal neuropharmacology model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · Tisserand & Young, Essential Oil Safety 2e - thujone constituent dermal maximum 0.25%EMA's public statement on thujone-containing herbal medicinal products emphasizes exposure control and describes convulsions, CNS disturbance, unconsciousness, and death in severe intoxication scenarios involving thujone-rich essential oil or preparations.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
The human and animal literature reviewed in this pass makes neurotoxicity the principal safety concern for grouped thujones; this is not a constituent class for casual benefit-forward copy.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
This grouped record should not inherit numeric claims indiscriminately from alpha-thujone or beta-thujone single-isomer records without making the scope explicit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
gaba_a_receptor_antagonism_like_neuroactivity
The reviewed toxicology literature consistently describes thujone neuroactivity in terms of GABAA receptor inhibition or antagonism-like effects that can produce excitation and convulsions.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
cyp2a6_led_metabolism_with_cyp3a4_and_cyp2b6_contributions
A toxicology review identified CYP2A6 as the principal metabolic enzyme for thujone, followed by CYP3A4 and to a lesser extent CYP2B6, which is relevant to metabolism and interaction framing.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- No single authoritative public CAS number cleanly represents the archive's grouped thujones bucket, so the CAS field is left null on purpose.
- Much of the literature separates alpha-thujone, beta-thujone, and alpha,beta-thujone mixtures, which limits how precisely grouped claims can be stated.
- Human dose-response evidence for isolated grouped thujones remains sparse compared with animal and regulatory literature.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.